BlackRock’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $261M | Buy |
15,409,023
+3,253,217
| +27% | +$45.5M | ﹤0.01% | 1628 |
|
|
2026
Q1 | $156M | Buy |
12,155,806
+1,878,957
| +18% | +$23.9M | ﹤0.01% | 1824 |
|
|
2025
Q4 | $92.4M | Buy |
10,276,849
+1,001,032
| +11% | +$13.8M | ﹤0.01% | 2152 |
|
|
2025
Q3 | $160M | Sell |
9,275,817
-751,358
| -7% | -$9.25M | ﹤0.01% | 1808 |
|
|
2025
Q2 | $94.1M | Sell |
10,027,175
-529,015
| -5% | -$4.34M | ﹤0.01% | 2087 |
|
|
2025
Q1 | $75.1M | Sell |
10,556,190
-301,503
| -3% | -$3.05M | ﹤0.01% | 2166 |
|
|
2024
Q4 | $127M | Buy |
10,857,693
+1,084,951
| +11% | +$16.9M | ﹤0.01% | 1946 |
|
|
2024
Q3 | $201M | Buy |
9,772,742
+175,135
| +2% | +$4.04M | ﹤0.01% | 1658 |
|
|
2024
Q2 | $215M | Buy |
9,597,607
+488,339
| +5% | +$11.6M | ﹤0.01% | 1563 |
|
|
2024
Q1 | $251M | Buy |
9,109,268
+98,573
| +1% | +$2.74M | 0.01% | 1493 |
|
|
2023
Q4 | $275M | Buy |
9,010,695
+877,905
| +11% | +$25.2M | 0.01% | 1425 |
|
|
2023
Q3 | $257M | Buy |
8,132,790
+77,827
| +1% | +$3.02M | 0.01% | 1376 |
|
|
2023
Q2 | $328M | Buy |
8,054,963
+706,344
| +10% | +$28.6M | 0.01% | 1226 |
|
|
2023
Q1 | $274M | Buy |
7,348,619
+93,373
| +1% | +$3.66M | 0.01% | 1323 |
|
|
2022
Q4 | $253M | Buy |
7,255,246
+1,127,106
| +18% | +$53.6M | 0.01% | 1360 |
|
|
2022
Q3 | $343M | Buy |
6,128,140
+240,741
| +4% | +$14.9M | 0.01% | 1075 |
|
|
2022
Q2 | $305M | Buy |
5,887,399
+285,660
| +5% | +$14.5M | 0.01% | 1216 |
|
|
2022
Q1 | $407M | Sell |
5,601,739
-18,637
| -0.3% | -$1.58M | 0.01% | 1129 |
|
|
2021
Q4 | $665M | Buy |
5,620,376
+89,381
| +2% | +$11.2M | 0.02% | 819 |
|
|
2021
Q3 | $742M | Buy |
5,530,995
+565,430
| +11% | +$85.6M | 0.02% | 713 |
|
|
2021
Q2 | $804M | Sell |
4,965,565
-306,061
| -6% | -$23.8M | 0.02% | 702 |
|
|
2021
Q1 | $423M | Buy |
5,271,626
+218,781
| +4% | +$14.7M | 0.01% | 1157 |
|
|
2020
Q4 | $275M | Sell |
5,052,845
-592,164
| -10% | -$21.5M | 0.01% | 1371 |
|
|
2020
Q3 | $112M | Buy |
5,645,009
+594,183
| +12% | +$12.4M | ﹤0.01% | 1811 |
|
|
2020
Q2 | $106M | Buy |
5,050,826
+1,258,528
| +33% | +$21.4M | ﹤0.01% | 1808 |
|
|
2020
Q1 | $46.4M | Buy |
3,792,298
+147,068
| +4% | +$1.98M | ﹤0.01% | 2094 |
|
|
2019
Q4 | $53.5M | Buy |
3,645,230
+64,632
| +2% | +$899K | ﹤0.01% | 2320 |
|
|
2019
Q3 | $47.8M | Buy |
3,580,598
+190,331
| +6% | +$3.03M | ﹤0.01% | 2314 |
|
|
2019
Q2 | $55.5M | Buy |
3,390,267
+208,548
| +7% | +$3.28M | ﹤0.01% | 2264 |
|
|
2019
Q1 | $54.3M | Buy |
3,181,719
+312,981
| +11% | +$4.67M | ﹤0.01% | 2224 |
|
|
2018
Q4 | $39.2M | Buy |
2,868,738
+124,341
| +5% | +$2.31M | ﹤0.01% | 2376 |
|
|
2018
Q3 | $78.5M | Buy |
2,744,397
+188,098
| +7% | +$5.47M | ﹤0.01% | 2123 |
|
|
2018
Q2 | $69.9M | Buy |
2,556,299
+833,337
| +48% | +$20.2M | ﹤0.01% | 2165 |
|
|
2018
Q1 | $36.3M | Buy |
1,722,962
+12,015
| +0.7% | +$295K | ﹤0.01% | 2448 |
|
|
2017
Q4 | $32.9M | Buy |
1,710,947
+31,662
| +2% | +$731K | ﹤0.01% | 2513 |
|
|
2017
Q3 | $41.7M | Buy |
1,679,285
+3,949
| +0.2% | +$74.4K | ﹤0.01% | 2392 |
|
|
2017
Q2 | $26.8M | Buy |
1,675,336
+731,992
| +78% | +$10.2M | ﹤0.01% | 2628 |
|
|
2017
Q1 | $13.3M | Buy |
943,344
+942,943
| +235,148% | +$12.7M | ﹤0.01% | 2982 |
|
|
2016
Q4 | $5K | Hold |
401
| – | – | ﹤0.01% | 3524 |
|
|
2016
Q3 | $7K | Sell |
401
-2,063
| -84% | -$39.9K | ﹤0.01% | 3456 |
|
|
2016
Q2 | $53K | Buy |
+2,464
| New | +$65.6K | ﹤0.01% | 2906 |
|
Other funds holding NTLA
AIM
RCM
RP
BlackRock's NTLA Position: Q2 2026 in Review
BlackRock increased its Intellia Therapeutics (NTLA) stake by 27% in Q2 2026, buying an estimated $45.5M and bringing the position to 15,409,023 shares worth $261M. The position accounts for ﹤0.01% of the portfolio, ranked #1628.
BlackRock first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. The position peaked at $804M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.
- BlackRock held 15,409,023 shares of Intellia Therapeutics worth $261M as of Q2 2026.
- BlackRock bought 3,253,217 Intellia Therapeutics shares in Q2 2026, an estimated $45.5M.
- Intellia Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1628 holding.
- BlackRock first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
- BlackRock's Intellia Therapeutics position peaked at $804M in Q2 2021.
- 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.